Highest-materiality recent filing
Cardinal Health Q3 revenue +11% to $60.9B, non-GAAP EPS $3.17 (+35%), raises FY26 outlook
Non-GAAP EPS $3.17, up 35% YoY; GAAP EPS $1.69, down 20% on $184M goodwill impairment in Navista & ION.
Revenue $65.6B (+19% YoY); GAAP diluted EPS $1.97 (+19%); non-GAAP diluted EPS $2.63 (+36%).
Cardinal Health raises FY2026 non-GAAP EPS outlook to at least $10.00, up from $9.65-$9.85
Raises FY2026 non-GAAP diluted EPS guidance to at least $10.00 from prior range of $9.65-$9.85.
Cardinal Health Q1 revenue $64B (+22%), non-GAAP EPS $2.55 (+36%); raises FY2026 guidance
Revenue $64B (+22% YoY); GAAP diluted EPS $1.88 (+11%); non-GAAP diluted EPS $2.55 (+36%).
Cardinal Health issues $1B in notes to partially fund Solaris Health acquisition
Issued $600M of 4.500% notes due 2030 and $400M of 5.150% notes due 2035.
Q4 revenue $60.2B flat YoY (+21% excluding contract expiration); non-GAAP EPS $2.08 (up 13%).
Cardinal Health raises FY25 EPS guidance to $8.15-$8.20; sets FY26 preliminary EPS $9.10-$9.30
Raising FY25 non-GAAP diluted EPS to $8.15-$8.20 (from $8.05-$8.15); 9% growth at midpoint.
Cardinal Health Q3 non-GAAP EPS $2.35, up 13% YoY; raises FY25 EPS guidance to $8.05-$8.15
Revenue $54.9B flat YoY; up 19% ex-customer contract expiration.
Cardinal Health Q2 non-GAAP EPS $1.93 (+2% YoY); guides FY25 $7.85-8.00, closes GI Alliance deal
Revenue $55.3B (-4% YoY; +16% ex-large customer expiration); GAAP EPS $1.65, non-GAAP EPS $1.93.
Cardinal Health raises FY2025 non-GAAP EPS guidance to high end of $7.75-$7.90 range
Now expects FY2025 non-GAAP EPS toward high end of $7.75 to $7.90, driven by Pharmaceutical & Specialty Solutions strength.
Cardinal Health enters $1.0B term loan for acquisitions of GI Alliance and Advanced Diabetes
$1.0B aggregate term loan facility to pay cash consideration and transaction costs for pending acquisitions of GI Alliance (majority equity) and Advanced Diabetes Supply Group.
Issued $500M of 4.700% Notes due 2026, $750M of 5.000% Notes due 2029, $1B of 5.350% Notes due 2034, and $650M of 5.750% Notes due 2054.
Cardinal Health acquires 71% of GI Alliance for ~$2.8B and ADSG for ~$1.1B
Acquires 71% stake in GI Alliance (gastroenterology MSO) for ~$2.8B cash; remaining ~29% callable at fair value after 3 years.
Cardinal Health Q1 GAAP EPS $1.70; Non-GAAP EPS $1.88, up 9% YoY; Raises FY25 guidance
Revenue $52.3B, down 4% (up 15% ex-large customer expiration); Pharmaceutical segment profit up 16% to $530M.
Q4 revenue $59.9B (+12% YoY); GAAP EPS $0.96, non-GAAP EPS $1.84 (+29%).
Cardinal Health Q3 non-GAAP EPS $2.08 (+20% YoY); raises FY24 EPS guidance to $7.30-$7.40
Revenue $54.9B (+9% YoY); GAAP diluted EPS $1.05; non-GAAP diluted EPS $2.08 (+20%).
Cardinal Health OptumRx contracts not renewed; reaffirms FY2024 non-GAAP EPS guidance $7.20-$7.35
OptumRx contracts expire June 2024; not renewed; 16% of FY2023 consolidated revenue.
Cardinal Health completes $1.15B senior notes offering in two tranches
Issued $650M of 5.125% notes due 2029 and $500M of 5.450% notes due 2034.
Cardinal Health Q2 revenue up 12% to $57.4B; non-GAAP EPS $1.82 (+38%); FY24 guidance raised
GAAP diluted EPS $1.43 vs. $(0.50) prior year; non-GAAP operating earnings $562M, up 20%.
Updated FY2024 non-GAAP diluted EPS guidance to high end of $6.75–$7.00.
Cardinal Health Q1 revenue +10% to $54.8B; raises FY24 non-GAAP EPS guidance to $6.75-$7.00
GAAP operating loss $14M due to $581M Medical goodwill impairment; GAAP diluted EPS $0.02.
Cardinal Health Q4 non-GAAP EPS $1.55 (+48%); raises FY24 guidance to $6.50-$6.75
Q4 revenue $53.5B (+13% YoY); non-GAAP EPS $1.55 (+48%) vs $1.05 prior year.
Cardinal Health raises FY2023 EPS outlook, provides FY2024 guide of $6.45-$6.70, $3.5B buyback
Narrows FY2023 non-GAAP EPS guidance to $5.65-$5.80 (mid-point 13% growth); preliminary FY2024 guidance $6.45-$6.70 (15% growth).
Cardinal Health Q3 revenue +13% to $50.5B; raises FY23 non-GAAP EPS guidance to $5.60-$5.80
Revenue $50.5B (+13% YoY); GAAP EPS $1.34 (vs -$5.05 loss); Non-GAAP EPS $1.74 (+20% YoY).
Cardinal Health Q2 revenue $51.5B, non-GAAP EPS $1.32; raises FY23 guidance
Revenue $51.5B, up 13% YoY; GAAP operating loss $119M on $709M goodwill impairment in Medical segment.
Cardinal Health appoints Aaron Alt as CFO effective Feb 10, 2023
Aaron Alt, 51, named CFO effective Feb 10, 2023; succeeds interim CFO Trish English.
GAAP operating earnings $137M, including $154M goodwill impairment; GAAP diluted EPS $0.40, down 57% YoY.
Cardinal Health cuts Medical segment Q1 FY23 guidance to $55M-$25M loss on glove inventory charges
Medical segment loss expected $55M-$25M for Q1 FY23, down from prior range of $20M loss to $20M profit.
Cardinal Health announces Pharmaceutical Segment CEO change; Crawford out, Weitzman in
Victor Crawford to step down as Pharmaceutical Segment CEO effective Sept 19, 2022; will stay until Nov 13 for transition.
Four new independent directors appointed: Steven Barg (Elliott), Michelle Brennan, Sujatha Chandrasekaran, Christine Mundkur, effective Sept 6, 2022.
Cardinal Health appoints CFO Jason Hollar as CEO; Q4 revenue up 11% to $47.1B
Jason Hollar, current CFO, becomes CEO effective Sept 1, 2022; Mike Kaufmann steps down.
On March 7, 2025, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Musslewhite and Sudhakar Ramakrishna to the Board, effective immediately.
On March 7, 2025, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Musslewhite and Sudhakar Ramakrishna to the Board, effective immediately.
On September 6, 2024 and September 8, 2024, respectively, Steven K. Barg and Sujatha Chandrasekaran, both members of the Board of Directors (the “Board”) of Cardinal Health, Inc. (the "Company") since 2022, informed the Company that they have decided not to stand for re-election to the Board when their terms expire at the 2024 annual meeting of shareholders.
On September 6, 2024 and September 8, 2024, respectively, Steven K. Barg and Sujatha Chandrasekaran, both members of the Board of Directors (the “Board”) of Cardinal Health, Inc. (the "Company") since 2022, informed the Company that they have decided not to stand for re-election to the Board when their terms expire at the 2024 annual meeting of shareholders.
On February 28, 2024, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Azelby to the Board, effective March 1, 2024, to serve until the 2024 annual meeting of shareholders and until his successor is elected and qualified or until his earlier resignation, removal from office, or death.
On August 10, 2023, Carrie S. Cox, a member of the Board of Directors (the “Board”) of the Company since 2009, informed the Company that she has decided not to stand for re-election to the Board when her term expires at the 2023 annual meeting of shareholders.
Mr. Alt will succeed Patricia M. English, who will continue to serve as interim CFO until February 10, 2023.
On December 16, 2022, the Board of Directors of Cardinal Health, Inc. (the “Company”) elected Aaron E. Alt, 51, as Chief Financial Officer (“CFO”) of the Company, effective February 10, 2023.
On September 8, 2022, Cardinal Health, Inc. (the “Company”) announced that Victor L. Crawford will cease to serve as Chief Executive Officer, Pharmaceutical Segment effective September 19, 2022.
Director Appointments Pursuant to the Cooperation Agreement, each of the New Directors was appointed to the Board effective September 6, 2022.
Director Appointments Pursuant to the Cooperation Agreement, each of the New Directors was appointed to the Board effective September 6, 2022.
Director Appointments Pursuant to the Cooperation Agreement, each of the New Directors was appointed to the Board effective September 6, 2022.
Max materiality 0.90 · Median 0.68 · Most common event earnings